バイオポリマーを用いたシャペロン （Hsp90）標的型抗癌剤ナノ粒子の設計と開発 by Rochani Ankit Kanaiyalal
バイオポリマーを用いたシャペロン （Hsp90）標的
型抗癌剤ナノ粒子の設計と開発
著者 Rochani Ankit Kanaiyalal
学位授与大学 東洋大学
取得学位 博士
学位の分野 バイオ・ナノサイエンス融合
報告番号 32663甲第420号
学位授与年月日 2017-03-25
URL http://id.nii.ac.jp/1060/00008972/
Creative Commons : 表示 - 非営利 - 改変禁止
http://creativecommons.org/licenses/by-nc-nd/3.0/deed.ja
Summary of Doctoral Thesis 
 
 
 
 
 
Design and Development of Nano-formulation 
for Chaperone (Hsp90) Targeted Anticancer 
Drugs Using Biopolymers 
 
 
 
Rochani Ankit Kanaiyalal 
Student ID: 4R10140003 
 
 
 
 
 
 
 
 
 
 
 
Doctoral Course 
Course of Bio Nano Fusion Science 
Graduate School of Interdisciplinary New Science 
Toyo University, Japan 
Academic Year 2016 
Summary 
 
Heat shock protein 90 (Hsp90) is chaperone that helps in protein folding process. . 
Structurally, each monomer of the dimeric Hsp90 consists of a) N-terminal domain, 
b) Charged linker region and c) C-terminal domain.  In cancer, Hsp90 serves as a hub 
for repair of the damaged client proteins that are associated to cancer growth and 
development. Inhibition of Hsp90 shuts down the molecular machinery that is 
essential for survival and development cancer cells. As a result Hsp90 is considered 
as a potential anticancer drug target for variety of cancers.  Most common focus of 
Hsp90 targeted therapy is to develop inhibitor that binds to ATP binding site of N-
terminal domain. The protein-folding pathway of Hsp90 works mainly due to binding 
of ATP to N-terminal site of protein. Competitive association of ligands to ATP 
binding site of Hsp90 causes cancer cell death due to disruption in the function of 
Hsp90. 17-allyl amino 17-demethoxy geldanamycin (17AAG) is an N-terminal 
binding Hsp90 inhibitor. The discovery 17AAG in 1995 lead to the foundation of 
Hsp90 targeted cancer therapy. The molecule entered advanced clinical trials to fight 
against variety of cancers. Since the advent of the era of Hsp90 inhibitors there nearly 
fifteen Hsp90 targeting molecules that have entered clinical trials against variety of 
cancer conditions. Off these inhibitors, 17AAG and Luminespib have been 
extensively studied for their pharmacological properties, safety and efficacy. Further, 
it is also been reported that Hsp90 inhibitors may work effectively as combination 
therapy for certain cancer conditions. There are recent studies that suggest that Hsp90 
inhibitors may also work extremely well with magnetic hyperthermia induced by 
Fe3O4 magnetic nanoparticles (MNPs). 
Most Hsp90 inhibitors encounter the problem of patient non-compliance due to their 
water insolubility and variable effects in various cancers. In order to solve this 
problem we developed bio-polymeric nanoformulation to explore the use of Hsp90 
inhibitors a) in combination with magnetic hyperthermia and b) bovine serum 
albumin loaded second generation Hsp90 inhibitor (Luminespib) that can be used 
against various cancers. We have subdivided present work into five main chapters and 
conclusion chapter. Following is the brief summary for each chapter: 
 
Chapter I: Heat Shock Protein 90 Targeted Nano Anti-Cancer Therapy 
Cancer disease has an extremely complex dynamics. Nearly two decades of Hsp90 
targeted drug discovery has shown that the mono-therapy with Hsp90 inhibitors 
seems to be relatively ineffective compared to combination treatment due to several 
cellular dodging mechanisms. In this article we have tried to analyze and review the 
Hsp90 and m-TOR mediated drug resistance mechanisms. By using this information 
we have discussed about the rationale behind use of drug combinations that includes 
both or any one of these inhibitors for cancer therapy.  
Currently, biodegradable nano vector (NV) loaded novel drug delivery systems 
(NDDS) have shown to resolve the problems of poor bioavailability. NVs of drugs 
like Paclitaxel, Doxorubicin, Daunorubicin and others have been successfully 
introduced for medicinal use. Drug delivery systems are considered as largest market 
accounting for 80% sales in nanomedicine sector. It was assumed that nearly 30% of 
value a drug is added by NDDS.  In 2006, it was reported that nanomedicines were 
estimated to contribute nearly 20 billion USD in the health care sector by 2012 in EU. 
However, the global nanomedicine market in 2009 was estimated to be 53 billion 
USD. On the other hand European technology platform (ETP) predicted that overall 
nanomedicine revenue would be in the range of 97 to 126 billion USD by 2016. It is 
estimated that the anticancer nanomedicine market is estimated to cover 33% of the 
total nanomedicine market in 2014. Hence, looking at the success of NVs, in this 
article we have also discussed about the progress made in the delivery of 
biodegradable NV loaded with Hsp90 and m-TOR targeted inhibitors in combinations 
regime. We have also discussed the possible ways by which the market success of 
biodegradable NVs can positively impact the clinical trials of anti-Hsp90 and m-TOR 
combination strategy. 
 
Chapter II: Instrumentation and Experimental Setup 
In our work we have synthesized nanoformulations of Hsp90 inhibitors for anticancer 
efficacy. In the present chapter, we have summarized basic principle for the 
instruments like scanning electron microscopes (SEM), transmission electron 
microscope (TEM), X-ray photoelectron spectroscopy (XPS), U.V visible 
spectroscopy, magnetic hyperthermia coil system and others. 
 
Chapter III: Dual mode of cancer cell destruction for pancreatic cancer therapy 
using Hsp90 inhibitor loaded polymeric nano magnetic formulation 
17- N-allylamino- 17-demethoxygeldanamycin (17AAG) has shown to provide 
considerable anticancer efficacy against pancreatic cancer when used in combination 
with other drugs. Further, magnetic hyperthermia has also shown to have promising 
effects against pancreatic cancer in combination with known cyto-toxic drugs under 
both target and non-targeted scenarios. Hence, in order to enhance the efficacy of 
17AAG against pancreatic cancer, we developed poly (lactic-co-glycolic acid) 
(PLGA) coated, 17AAG and Fe3O4 loaded magnetic nanoparticle formulations by 
varying the relative concentration of polymer. Our study shows that 1:1:10 drug 
loaded polymeric MNPs (DMNP) formulation had relatively better results for particle 
characterization studies. It was observed from the drug release profile that the amount 
of drug released from 1:1:10 formulation was relatively more compared to 1:1:20. We 
also found that polymer concentration affects the magnetic strength formulations. We 
evaluated drug and magnetic hyperthermia induced in vitro cytoxicity for our 
nanoformulations. We were also able to see that our aqueous dispensable 
formulations were able to provide anti-pancreatic cancer activity for MIA PaCa-2 cell 
line in dose and time dependent manner in comparison to mice fibroblast cell lines 
(L929).  Moreover, the in-vitro magnetic hyperthermia against MIA PaCa-2 provided 
proof principle that our 2-in-1 particles may work against cancer cell lines effectively. 
This study is a first step towards the improvement over the currently available regime 
for pancreatic cancer therapy. Hence, we believe that our study can be considered for 
the further molecular and in vivo evaluations. 
 
Chapter IV: Molecular Modeling for Interaction of Anticancer drugs with 
Protein Based Carriers. 
In the present study we have used Lamarkian genetic algorithm based AutoDock for 
the identification of probable binding site for Luminespib on BSA. However, since 
there is no reference ligand to map the binding sites on BSA, we scanned entire 
surface of the protein using blind docking method to find an unbiased binding site for 
Luminespib. We believe that further analysis of inhibition constants (Ki), % 
frequency and structure of the conformations obtained with grid size of a) 60 x 60 x 
60, b) 90 x 60 x 80 with PM6 partial charge calculations should provide a more 
reliable information about the binding site for Luminespib on BSA. Perhaps, the wet 
lab experiments like fluorescent quenching and XPS may also confirm the binding of 
Luminespib to BSA. 
 Chapter V: Luminespib Loaded Protein Based Nanoformulation for Hsp90 
Targeted Cancer therapy 
Bovine serum albumin (BSA) is an important and abundant protein for buffering 
various biological functions. BSA has also been extremely useful biomaterial for 
preparation of NPs that can be used as novel drug carrier for anticancer drugs. BSA 
based NPs have be extremely successful and are translated for clinical use as 
anticancer drugs. For example Paclitaxel loaded BSA NPs called as Abraxane by 
Abraxis pharmaceuticals have entered for clinical use against pancreatic cancer, 
breast cancer, lung cancer and others. Hence, use of the BSA based platform for 
formulation of Hsp90 inhibitors may also prove useful. Luminespib (NVP-AUY922) 
is a new generation Hsp90 inhibitor that was introduced recently for advance clinical 
trials as mentioned previously. However, like many other Hsp90 inhibitors, it is also a 
hydrophobic molecule. We have developed BSA NP formulation for Luminespib 
using classical desolvation method. We found that Luminespib interacts by non-
covalent reversible interactions with BSA to form drug loaded BSA conjugated NPs 
(DNPs). Our study suggests that Luminespib binds to domain I of BSA by forming 
thirteen reversible hydrophilic and hydrophobic interactions. We have also confirmed 
that binding of Luminespib to BSA using fluorescence quenching experiment. We 
found that with the increase in relative concentration of Luminespib there was 
reduction in fluorescence intensity. This clearly indicates binding of drug to BSA 
protein. We further confirmed binding of Luminespib to BSA by using XPS. We 
found presence of signature peaks associated to drug in Luminespib-BSA NPs in 
comparison to native or blank BSA NPs. Our U.V spectroscopy study suggests that 
encapsulation efficiency and drug loading in Luminespib-BSA nanoconjugates was 
found to be 48.22 ±1.948 % and 4.28±1.94 % respectively. We believe that this 
formulation can be used for further evaluation of the anticancer therapy.  
Chapter VI: Conclusion 
Our analysis suggests that NP based NDDS can help in developing water dispensable 
colloidal dispersion for hydrophobic Hsp90 inhibitors. It was observed that Hsp90 
inhibitors works better in certain cancer as single therapy while in others they work 
better in combination regime. Hence, cancer treatment seems to be done on a 
personalized basis. It was observed that 17AAG proved to be effective in combination 
therapy. As a result our drug loaded polymeric magnetic nanoformulation showed 
Hsp90 inhibitor and magnetic hyperthermia induced cytotoxicity in a concentration 
dependent manner. We altered relative polymeric concentration to give two types of 
formulations as 1:1:20 and 1:1:10. We observed that nanoformulation with ratio of 
drug to Fe3O4 to polymer as 1:1:10 exhibited relatively better pharmacological 
response against pancreatic cancer. Further, we have also developed Luminespib 
loaded bovine serum albumin NPs. Here, we used drug to polymer ratio as 1:10. We 
found that the drug forms non-covalent interactions with BSA to form drug-BSA 
nanoconjugates. We also observed sustained release of drug from our 
nanoformulation. The nanoparticles were found to be of size around 222 nm. Our 
studies clearly indicate that the smart nanoformulation of hydrophobic Hsp90 
inhibitors can help increasing the patient compliance by lowering the dose related 
toxicity that is mostly attributed to the classical DMSO based formulations. 
 
